Abstract
Cognitive impairment underpins some of the clinical spectrum of the cerebrovascular disease (CVD), as well as contributes to the patient´s impaired social and behavioral functioning, and the higher mortality. When cognitive function is affected by CVD, we name it as vascular cognitive impairment (VCI). The cognitive impairment may be mild, or may be severe enough to warrant a diagnosis of dementia. Pure vascular dementia is not common. Because of that the concept of mixed dementia has been included in the clinical diagnosis of VCI.
Despite a general emphasis in the international literature on the primary and secondary prevention of CVD to avoid vascular dementia or their combination with Alzheimer’s disease, the controversy concerning their diagnostic criteria and optimal treatment is still open. Given its growing burden, the prevention and treatment of CVD and the spectrum of VCI are critical priorities for clinical care and research.
We performed a selective review about the current status of vascular dementia, mild cognitive impairment due to CVD, and mixed dementia, with special emphasis on available evidence of pharmacological strategies for treatment and prevention from controlled clinical trials.
Keywords: Alzheimer's disease, cerebrovascular disease, post-stroke dementia, vascular cognitive impairment, vascular dementia, vascular risk factors.
Current Psychopharmacology
Title:Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating
Volume: 3
Author(s): Maria Julieta Russo and Ricardo Francisco Allegri
Affiliation:
Keywords: Alzheimer's disease, cerebrovascular disease, post-stroke dementia, vascular cognitive impairment, vascular dementia, vascular risk factors.
Abstract: Cognitive impairment underpins some of the clinical spectrum of the cerebrovascular disease (CVD), as well as contributes to the patient´s impaired social and behavioral functioning, and the higher mortality. When cognitive function is affected by CVD, we name it as vascular cognitive impairment (VCI). The cognitive impairment may be mild, or may be severe enough to warrant a diagnosis of dementia. Pure vascular dementia is not common. Because of that the concept of mixed dementia has been included in the clinical diagnosis of VCI.
Despite a general emphasis in the international literature on the primary and secondary prevention of CVD to avoid vascular dementia or their combination with Alzheimer’s disease, the controversy concerning their diagnostic criteria and optimal treatment is still open. Given its growing burden, the prevention and treatment of CVD and the spectrum of VCI are critical priorities for clinical care and research.
We performed a selective review about the current status of vascular dementia, mild cognitive impairment due to CVD, and mixed dementia, with special emphasis on available evidence of pharmacological strategies for treatment and prevention from controlled clinical trials.
Export Options
About this article
Cite this article as:
Russo Julieta Maria and Allegri Francisco Ricardo, Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating, Current Psychopharmacology 2014; 3 (1) . https://dx.doi.org/10.2174/2211556003666140702190144
DOI https://dx.doi.org/10.2174/2211556003666140702190144 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
How Would Composite Traditional Chinese Medicine Protect the Brain – An Example of the Composite Formula “Pien Tze Huang”
Current Medicinal Chemistry Liquid Chromatography Coupled to Electrochemical Detection and Mass Spectrometry for the Determination of Phenolic Compounds in Food and Beverages
Current Analytical Chemistry New Drugs for HDL-C Disorders: The Beginning
Current Medicinal Chemistry Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi
Current Medicinal Chemistry Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Management of Hypertension in Patients with Aortic Valvular Stenosis
Current Hypertension Reviews Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews Lipids and Non-Cardiac Vascular Disease: A Lecture Overview
Current Vascular Pharmacology Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance
Current Cardiology Reviews Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Epsilon Waves as an Extreme Form of Depolarization Delay: Focusing on the Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
Current Cardiology Reviews Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Mechanisms and Characteristics of Sulfonylureas and Glinides
Current Topics in Medicinal Chemistry The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design The Role of Mineral Deficiencies in Insulin Resistance and Obesity
Current Diabetes Reviews